In infantile leukemias and therapy-related leukemias, the MLL gene is frequently found to be disrupted and fused to various translocation partner genes, such as AF4/FEL, LTG9/AF9 and LTG19/ENL as a result of 11q23 translocations. We previously showed that the Nterminal portion common to various chimeric MLL products, as well as to MLL-LTG9 and MLL-LTG19, localizes in the nuclei, and therefore suggested that it might play an important role in leukemogenesis. In the present study, MLL-AF6 chimeric products found in the t(6;11) (q27;q23) translocation were analysed since AF6, a Ras-binding protein, exhibits a dierent subcellular localization from that of LTG9/AF9 and LTG19/ENL. Immuno¯uorescence staining data and cell fractionation analyses demonstrated that MLL-AF6 chimeric products localize in the nuclei despite the fact that AF6 itself localizes in the cytoplasm, con®rming the importance of the nuclear localization of chimeric MLL products. The region in the N-terminal portion of MLL responsible for this nuclear localization was examined and found to be a region containing AT-hook motifs.
Introduction
Chromosomal translocations have been shown to play important roles in tumorigenesis in leukemias and solid tumors (Rabbitts, 1994) . Analysis of 11q23 translocations, commonly observed in infantile leukemias (Abe and Sandberg, 1984; Kaneko et al., 1986; Pui et al., 1991) and therapy-related leukemias (Pui et al., 1989) , has revealed the presence of the MLL/ ALL-1/HRX gene encoding a 432 kDa protein with AT-hook DNA-binding motifs (Gu et al., 1992; Tkachuk et al., 1992; Yamamoto et al., 1993a,b) at 11q23. The MLL gene also has zinc ®nger motifs which have been named PHD ®ngers (Aasland et al., 1995) or the LAP domain . The zinc ®nger motifs and the C-terminal portion of MLL show signi®cant homology to Drosophila trithorax. A cysteine-rich region showing high homology to the mammalian DNA methyltransferase (Ma et al., 1993) , located on the N-terminal side of the zinc ®nger motifs has also been noted. However, the biological role of MLL in mammalian cells and the mechanism of leukemogenesis still remains to be elucidated. In leukemias with 11q23 translocations, MLL is disrupted and the N-terminal portion, including the AThook motifs and the DNA methyltransferase homology region, is fused to various translocation partner genes, such as AF4/FEL, LTG9/AF9 and LTG19/ENL (Gu et al., 1992; Iida et al., 1993; Morrissey et al., 1993; Nakamura et al., 1993; Tkachuk et al., 1992; Yamamoto et al., 1993a,b) . Although more than ten dierent chromosomal translocation partner genes have been identi®ed (Thirman et al., 1993; Trent et al., 1989) , no shared common structure has been recognized among the partner gene products (Bernard et al., 1994; Chaplin et al., 1995; Corral et al., 1993; Iida et al., 1993; Mitani et al., 1995; Nakamura et al., 1993; Prasad et al., 1993; Thirman et al., 1994; Tse et al., 1995; Yamamoto et al., 1993b) . We previously demonstrated that the chimeric MLL products MLL-LTG9 and MLL-LTG19, as well as MLL-Zf (7), the N-terminal portion common to various chimeric MLL products, localize in nuclei (Joh et al., 1996) . These data suggest that the N-terminal portion of the MLL gene caused by truncation might play a pivotal role in the nuclei responsible for leukemogenesis, although the possible role of the partner gene region cannot be disregarded.
AF6, a fusion partner of the MLL gene has recently been identi®ed as a GTP-Ha-Ras binding protein (Kuriyama et al., 1996) . It has a Rasinteracting domain and a Dlg homology repeat (DHR) motif which is thought to function in the formation of protein complexes at the junction of the plasma membrane and the cytoskeleton (Lue et al., 1994) . Since the chimeric MLL-AF6 gene found in the t(6;11) (q27;q23) translocation includes all of AF6 except its N-terminal 35 amino acids, leaving both the Rasinteracting domain and DHR motif intact, identification of where the MLL-AF6 chimeric products localize in the cell is important for elucidation of the mechanism of leukemogenesis resulting from MLL translocations.
In this study we examined the subcellular localization of MLL-AF6 transiently expressed in COS7 cells and in a CTS cell line with t(6;11) (q27;q23) translocation derived from an acute myeloid leukemia patient (Kakuda et al., 1996) . Furthermore, in order to clarify the region of the N-terminal portion of MLL responsible for nuclear localization, we generated deletion mutants and examined their subcellular distribution.
Results

Western blot analysis of COS7 cell transfectants and CTS cell line
The six expression constructs used are shown in Figure  1 . Anity puri®ed antibodies against the recombinant N-terminus of MLL (N-MLL) (Joh et al., 1996) and GST-AF6 (1130 ± 1612 aa) fusion products (Kuriyama et al., 1996) were used for Western blot analysis. Figure 2a illustrates antibody reactivity data obtained with the COS cell transient expression system. The AF6 construct gave rise to a speci®c band at around 180 kDa, which was detected by the anti-AF6 antibody and close to the predicted size of 182 kDa (lane 2). The antibody against N-MLL detected a speci®c band at approximately 175 kDa of tMLL close to the predicted size of 147 kDa (lane 5). The band indicated by an arrowhead detected by the anti-N-MLL antibody in the MLL transfectant (lane 4) migrated more slowly than the highest size marker used (thyroglobulin large subunit, 330 kDa). Using the three size markers of 330 kDa, 220 kDa (ferritin subunit) and 200 kDa (myosin), we sized this band at about 410 kDa, again close to the predicted size of 432 kDa (lane 4). Since the 410 kDa band in the lysate of a mock transfectant in the same position as the transfected MLL product is detectable by long exposure, the 410 kDa band in the MLL transfectant is implicated as the speci®c MLL product identical to the endogenous one (Joh et al., 1996) .
In order to con®rm the size, puri®ed DNA-activated protein kinase (p470, DNA-PKcs) protein (Connelly et al., 1996; Teraoka et al., 1996;  kindly provided by Dr H Teraoka, Medical Research Institute, Tokyo Medical and Dental University) was placed on the same polyacrylamide gel as the MLL lysates. The DNAPKcs protein detected by the anti-p470 antibody (Serotech, Oxford, UK) migrated more slowly than MLL products and was sized at about 460 kDa on the basis of the 330 kDa, 220 kDa and 200 kDa markers; this size was close to the predicted size of 470 kDa (lane 6). The extra bands in lanes 2, 4 and 5 are possibly degraded or prematurely terminated products because no such bands were found in the mock transfected cells (lanes 1 and 3) . In the MLL-AF6 transfectant, the speci®c bands were also detected by both anti-AF6 and anti-N-MLL antibodies (lanes 8 and 9) at a higher position than the 330 kDa marker, indicating that the construct results in the in-frame chimeric product. We calculated the size as about 360 kDa with the size markers and DNA-PKcs protein. The extra bands around 200 kDa, found in lanes 7 and 8, are likely to be endogenous AF6 of COS7 cells.
The CTS cell line with the t(6;11)(q27;q23) translocation was examined by Western blot analysis using anti-AF6 and anti-N-MLL antibodies (Figure 2b) . By calculating the molecular mass of MLL-AF6 products with the aid of 330 kDa and 220 kDa markers, a speci®c MLL-AF6 band of 360kDa was detected by both anti-AF6 and anti-N-MLL antibodies (lanes 3 and 6). The size of this band was identical to that detected in ) and to Drosophila trithorax ( ) are indicated in the 3969 aa MLL polypeptide (Yamamoto et al., 1993b; Ma et al., 1993) . The Ras-interacting domain ( ) and DHR motif ( ) are indicated in the 1612 aa AF6 polypeptide Kuriyama et al., 1996) . MLL-LTG9 has a fusion site at aa number 1444 of MLL with aa number 376 of LTG9 ( ) giving rise to a 1637 aa polypeptide (Iida et al., 1993; Nakamura et al., 1993) . Numbers (above and under the products) represent amino acid positions. Predicted molecular mass based on the amino acid composition is shown in parentheses the COS7 cells transfected with the MLL-AF6 expression vector. These results suggest that MLL-AF6 chimeric products are synthesized in vivo in leukemias with t(6;11)(q27;q23). The extra bands in lanes 2, 3, 5 and 6 are possibly degraded or prematurely terminated products because no such bands were found in the cytoplasmic fractions (lanes 1 and 4).
MLL and MLL-AF6 chimeric products localize in the nucleus whereas AF6 localizes in the cytoplasm
Immuno¯uorescence staining was used to study the subcellular localization of COS7 cells transiently transfected with the expression vectors of MLL, tMLL, AF6, MLL-AF6, LTG9, MLL-LTG9 and the control vector pCXN2 (Figure 3 ). MLL, LTG9 and MLL-LTG9 products localized in the nuclei of the transfected cells as described previously (Joh et al., 1996) . The tMLL product also localized in the nuclei in a similar fashion to that for MLL-Zf (7) products (Joh et al., 1996) . In contrast, the AF6 product was found to localize in the cytoplasm of transfected cells without any intense signals in the nuclei. MLL-AF6 signals were only evident in the nucleus, but no intense signals were observed in cells transfected with the control vector pCXN2 (data not shown).
The nuclear localization of MLL-AF6 was further con®rmed by cell fractionation with Western blot analysis ( Figure 2b ). Lamin B was used as the nuclear fraction marker (Franke, 1987) and b -tubulin as the cytoplasmic fraction marker (Birkett et al., 1985) . An MLL-AF6 speci®c band of 360 kDa was detected (Joh et al., 1996) for the LTG9 (e) constructs in the CTS nuclear fraction by both anti-AF6 and anti-N-MLL antibodies (lanes 2 and 5).
The AT-hook motif region of MLL is responsible for nuclear localization of MLL and chimeric products
Since chimeric MLL products and the truncated MLL products, MLL-Zf(7) and tMLL, were found to localize in the nuclei, we investigated which region was responsible. COS7 cells were transfected with MLL-Zf(7), MLL-tAT, MLL-AT(7), MLL-MT(7), MLL-tMT constructs and the control vector pCEV29F3 (Figure 4) , and the products were examined by immuno¯uorescence staining ( Figure 5 ) and Western blot analysis ( Figure 6 ) using either anti-Flag M2 monoclonal (Eastman Kodak, New Haven, USA)
or anti-N-MLL antibodies. As shown in Figure 6a , MLL-tAT, MLL-AT(7), MLL-MT (7) and MLLtMT products were detected at approximately 39 kDa (lane 2), 60 kDa (lane 3), 41 kDa (lane 4) and 35 kDa (lane 5), respectively. MLL-Zf(7) protein was detected at about 155 kDa (lane 7). Immunostaining data revealed that MLL-Zf(7), tAT, AT(7) and tMT products localized in the nuclei while MT(7) products localized in both the nucleus and the cytoplasm. No intense signals were observed in cells transfected with the control vector pEV29F3 (data not shown).
Western blot analysis with cell fractions showed localization patterns partly dierent from those observed in the immuno¯uorescence study ( Figure 6 ). COS7 cells were transfected with MLL-Zf(7), MLLtAT, MLL-AT(7), MLL-MT(7), MLL-tMT constructs and the control vector pCEV29F3 (Figure 4) , and their whole, nuclear, and cytoplasmic fraction lysates were obtained. Figure 6b illustrates that the MLL-Zf(7) and MLL-tAT products were detected only in the nuclear fraction, while MLL-AT(7), MLL-MT(7), and MLL-tMT products were also found in the cytoplasm. Lamin B and b-tubulin were used as, respectively, the nuclear and cytoplasmic fraction markers as described above. 5) and anti-N-MLL antibodies (lanes 6 and 7). 10% (lanes 1 to 5) and 6% (lanes 6 and 7) polyacrylamide gel was used for the experiments. (b) Transfected COS7 cells were fractioned and reacted by anti-N-MLL for MLL-Zf(7) products and by anti-Flag M2 for MLLtAT, MLL-AT(7) MLL-MT(7) and MLL-tMT products. AntiLamin B and anti-b-tubulin antibodies were used to examine cell fractionation. (C: cytoplasmic fractions; N: nuclear fractions; W: whole lysates)
Nuclear localization of MLL ± AF6 involved in 11q23 leukemia T Joh et al
Discussion
Many lines of evidences demonstrate that truncations of MLL are restricted within a 0.9 kb fragment in cDNA and a 8.5 kb fragment in genome DNA in humans (Bernard et al., 1994; Chaplin et al., 1995; Corral et al., 1993; Iida et al., 1993; Mitani et al., 1995; Prasad et al., 1993; Thirman et al., 1993 Thirman et al., , 1994 Trent et al., 1989; Tse et al., 1995; Yamamoto et al., 1993b) . Ten translocation partner genes fused to MLL have been cloned to date, but no common structure has been found (Bernard et al., 1994; Corral et al., 1993; Mitani et al., 1995; Nakamura et al., 1993; Tkachuk et al., 1992; Tse et al., 1995) , suggesting that the N-terminal portion of MLL plays an important part in leukemogenesis. We previously demonstrated that two chimeric products, MLL-LTG9 and MLL-LTG19, localize in the nuclei in a similar fashion to that of MLL and MLL-Zf(7) products (Joh et al., 1996) . Since both LTG9 and LTG19 have nuclear localization signals, and in fact localize in nuclei (Joh et al., 1996) , it is clearly important to determine whether chimeric MLL products with partner genes having a dierent subcellular localization pattern show a similar nuclear localization. AF6, a Ras binding cytoplasmic protein (Kuriyama et al., 1996) , appears to be a very suitable partner for this purpose. Although AF6 showed cytoplasmic localization in line with its DHR motifs, both immuno¯uorescence study and cell fractionation analysis of the chimeric MLL-AF6 products demonstrated nuclear localization even though the motifs remained intact. This was the case for both the COS cell expression system (Figure 2a ) and the cell line CTS with the t(6;11)(q27;q23) translocation (Figure 2b ). These results suggest that the site of action for chimeric MLL products is in the nucleus and that the N-terminal portion of MLL de®nes their localization. However, it is possible that a small amount of these products remaining in the cytoplasm and not detected by this antibody constitutes a functionally releveant fraction.
Use of plasmids with deletion mutants and immuno¯uorescence staining in a COS cell expression system showed that MLL-Zf(7), MLL-tAT, MLLtAT(7) and MLL-tMT products were detected only in the nucleus, but that MLL-MT(7) products were detected in both the nucleus and cytoplasm. Cell fraction with Western blot analysis demonstrated that MLL-Zf(7) and MLL-tAT products ( Figure 5 ) as well as MLL, tMLL, MLL-LTG9 and MLL-AF6 products ( Figure 3) were detected only in the nuclear fraction, while MLL-AT(7), MLL-MT(7) and MLL-tMT products were detected in both the nuclear and cytoplasmic fraction ( Figure 5 ). The dierences in localization shown by immuno¯uorescence and fractionation studies may have been due to dierences in the experimental procedures. Whole cells were directly ®xed in the immuno¯uorescence procedure, while fractionated cells were treated with 0.5% NP40 for 10 min on ice in the case of fractionation. Under these conditions, MLL-Zf(7) and MLL-tAT products, as well as MLL, MLL-Zf(7), MLL-LTG9 and MLL-LTG19 (Joh et al., 1996) remained localized in the nuclei, suggesting that the AT-hook DNA binding motifs shared by all these constructs play an important role in nuclear localization.
Analysis of MLL gene targeting has demonstrated haploinsuciency for proper segment identity through control of the expression of Hox genes in MLL+/7 mice (Yu et al., 1995) . Furthermore, almost all cases of 11q23 leukemia show that one allele which is not involved in translocation remains intact (Yamamoto et al., 1994; Iida et al., 1993) . Therefore, it is important to clarify if haploinsuciency may lead to leukemic transformation or if the chimeric products have dominant activity under these circumstances. The report by Yu et al. (1995) mentions no leukemia observed in MLL+/7mice. Recently, Corral et al. (1996) utilized homologous recombination (knock-in model system), resulting in an MLL-AF9 genome organization, to demonstrate the importance of a fusion partner gene, AF9 (LTG9), for the development of myeloid leukemia. In their system, it is important to note that none of the ES cells with MLL truncation contributed to any blood cells, indicating an important role of the MLL gene for hematopoietic cell dierentiation. The possible difference between the MLL+/7mouse of Yu et al. (1995) and the knock-in model system of Corral et al. (1996) in their contribution to hematopoietic cells is that the former lacked truncated MLL products while the latter expressed them, suggesting that the MLL truncation alters hematopoietic cell dierentiation. ES cells with an MLL-AF9 chimeric construct might develop, through an as yet unknown mechanism, into hematopoietic cells while the truncated MLL without a fusion partner does not. These ®ndings suggest that chimeric MLL products play indeed an important role in leukemogenesis.
Our data demonstrating nuclear localization of MLL-AF6 chimeric products provides support for a link between these products and events in the nuclei. However, it is not yet clear if the chimeric products function as oncogenes or as dominant negative products which inhibit normal MLL function. Our previous ®nding that the N-terminal portion alone can block dierentiation in 32Dc13 cells is in line with the concept of a dominant negative mechanism (Joh et al., 1996) , but more detailed studies of the biological roles of translocation partner genes, as well as of MLL, are required before the complex issue of leukemogenesis involving the MLL gene can be resolved.
Materials and methods
Expression vector construction
The plasmids pCXN2, pCXN2-MLL, pCXN2-MLL-LTG9, PCXN2-LTG9 and pCXN2-MLL-Zf(7) were described previously (Joh et al., 1996) . Plasmids pCXN2-tMLL (1 ± 1362 aa), for the expression of the N-terminal portion of MLL at the breakpoint in t(6;11) (q27;q23) , pCXN2-MLL-AF6 (MLL, 1 ± 1362 aa; AF6, 36 ± 1613 aa), for the expression of MLL-AF6 chimeric products, and pCXN2-AF6 (1 ± 1613 aa), for the expression of full length AF6, were constructed as follows (Figure 1) . The 4086 bp cDNA fragment encoding the truncated MLL (tMLL, 1 ± 1362 aa) was ampli®ed by polymerase chain reaction (PCR) using LA Taq (TaKaRa, Tokyo, Japan) from pCXN2-MLL. This cDNA fragment with an arti®cial SalI site at the N-terminal and an arti®cial XhoI site at the C-terminal was cloned into the XhoI site of pCXN2 (Niwa et al., 1991) to produce pCXN2-tMLL. Full-length AF6 cDNA (4839 bp) was cloned by PCR ampli®cation using LA Taq from a HeLa cell cDNA library. A fragment with an arti®cial XhoI site at both terminals was cloned into the XhoI site of pCXN2 to obtain pCXN2-AF6. The 4534 bp cDNA fragment encoding the truncated AF6 (36 ± 1612 aa) was ampli®ed by PCR using LA Taq from pCXN2-AF6. This fragment with an arti®cial XhoI site at both terminals was cloned into the XhoI site of pCXN2-tMLL to generate pCXN2-MLL-AF6. In order to obtain ®ve deletion mutants of MLL, pCEV29F3-MLL-Zf(7) (1 ± 1250 aa), pCEV29F3-MLL-tAT (1 ± 320 aa), pCEV29F3-MLL-AT(7) (321 ± 748 aa), pCEV29F3-MLL-MT(7) (749 ± 1040 aa) and pCEV29F3-MLL-tMT (1041 ± 1250 aa) were constructed as follows (Figure 4) . pCEV29F3, kindly provided by Dr T Miki at NCI, Bethesda, MD, contains an M-MLV LTR promoter, a Kozak consensus sequence followed by three repeats of¯ag tags in frames, multiple cloning sites following the¯ag tags and SV40 ori. The cDNA fragment for MLL-Zf(7) was obtained from a plasmid, pCXN2-MLL-Zf (7), by BamHI digestion, and cloned into the BamHI site of pCEV29F3 to generate pCEV29F3-MLLZf(7). The other four cDNA fragments were all ampli®ed by PCR using LA Taq from pCXN2-MLL-Zf(7). cDNA fragments for MLL-tAT with an arti®cial BamHI site at the N-terminal and an arti®cial EcoRI site at the Cterminal, MLL-AT (7) with an arti®cial BamHI site at the N-terminal and an arti®cial Bg1II site at the C-terminal, MLL-MT (7) with an arti®cial Bg1II site at the Nterminal and an arti®cial EcoRI site at the C-terminal and MLL-tMT with arti®cial BamHI sites at both terminals were cloned into the BamHI or BamHI-EcoRI sites of pCEV29F3 in frame to¯ag tags to obtain pCEV29F3-MLL-tAT, pCEV29F3-MLL-AT(7), pCEV29 F3-MLL-MT(7) and pCEV29F3-MLL-tMT. All PCRs were performed according to the manufacturer's instruction: 20 s degeneration at 948C, 3 min annealing and extension at 688C and 30 cycles ampli®cation.
Cell culture and transfection
HeLa cells and COS7 cells were grown in Iscove's medium supplemented with 5% fetal calf serum (FCS). The CTS cell line with t(6;11) (q27;q23) was established by Dr H Kakuda (Kakuda et al., 1996) and the KOPB26 cell line with t(9;11) (p22;q23) by Dr S Nakazawa (Yamamoto et al., 1994) . Both were cultured in RPMI 1640 with 5% FCS. Transfection into COS7 cells using LIPOFECTAMINE (Life Technologies, Maryland, U.S.A.) was performed as described previously (Joh et al., 1996) .
Western blot analysis
Transfected COS7 cells grown in 10 cm dishes were collected by trypsinization, washed in phosphate buered saline (PBS), centrifuged, resuspended in 200 ml of 16SDS ± PAGE sample buer (62.5 mM Tris, pH 6.8, 2% SDS, 10% glycerol, 5% 2-mercaptoethanol, 0.01% bromophenol blue) and boiled for 5 min. 3610 6 cells of CTS were washed in PBS, centrifuged to yield cell pellets, resuspended in 150 ml of 16SDS ± PAGE sample buer and boiled for 5 min. For preparation of nuclear and cytoplasmic fractions, washed cells were suspended in 100 ml of hypotonic lysis buer (10 mM Tris, pH 7.4, 10 mM NaCl, 3 mM MgCl 2 , 0.5% NP-40, 0.2 mM PMSF, 100 mg/ml aprotinin, 0.25 mM leupeptin) per 1610 7 cells on ice for 10 min. The suspensions were then centrifuged in microtubes at 3000 r.p.m. at 48C for 3 min and the supernatant was transferred into new microtubes. The pellets were washed with hypotonic lysis buer and the nuclei were spun again. The resultant pellets were suspended in 150 ml of 16SDS ± PAGE sample buer and boiled for 5 min, then used as nuclear fraction samples. The transferred supernatant was further centrifuged at 10 000 r.p.m. at 48C for 10 min and again transferred. A one-third volume of 46SDS ± PAGE sample buer was then added and after boiling for 5 min, the resultant samples were used as the cytoplasmic fraction. Ten ml aliquots of these lysates were placed on 6*10% SDS-polyacrylamide gels and transferred onto PVDF membrances (Millipore, Bedford, USA). In the experiments with the lysates of MLL, tMLL and DNA-PKcs, ProSieve 50 gel solution (FMC BioProducts, Rockland, USA) was used in place of acrylamide because it allowed for an accurate analysis of the size of proteins larger than 200 kDa. The membranes were then blocked with blocking buer (3% nonfat dry milk and 2% BSA in PBS containing 0.05% NaN 3 ) for 1 h at 378C. After washing with 0.05% Tween 20 on PBS (T-PBS), the membranes were incubated with 1 to 5 mg/ml of antibodies in blocking buer at 48C overnight, washed extensively in T-PBS and exposed to horseradish peroxidase-conjugated anti-rabbit IgG (Immuno-Biological Laboratories, Gumma, Japan) diluted to 1 : 1000*2000 in blocking buer without NaN 3 . After incubation at room temperature for 45 min, the membranes were washed with T-PBS, and visualized with the aid of an ECL detection kit (Amersham-Japan, Tokyo).
Immuno¯uorescence staining COS7 cells were grown on glass slides in Falcon 1020 dishes and transfection was carried out as described above. Transfected COS7 cells were ®xed in 4% paraformaldehyde in PBS for 15 min at room temperature. After washing with PBS, the cells were permeabilized in 0.2% Triton-X in PBS for 2 min at room temperature and then washed extensively. The specimens were blocked with 2% BSA in PBS for 30 min at room temperature and washed with 0.05% T-PBS three times. The ®rst antibodies were applied at 5*10 mg/ml in 2% normal goat serum in PBS for 1 h at room temperature. After three washings with T-PBS, the cells were incubated with FITC-conjugated goat anti-rabbit IgG (Immuno-Biological Laboratories) diluted to 1 : 100 in 2% normal goat serum in PBS for 30 min at room temperature. The specimens were then washed two times with T-PBS and once with PBS, then mounted in PermaFluor Aqueous Mounting Medium (IMMUNON, Pittsburgh, USA). For observation of the specimens confocal¯uorescence microscopy (BioRad, Tokyo, Japan) was used.
